|
Name |
(2R)-6-[(1E,3E,5E)-6-[(2R,3R,3aR,4R,5R,6aR)-2-ethyl-3,4-dihydroxy-3,3a-dimethyl-2,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]hexa-1,3,5-trienyl]-2,3,3,7-tetramethyl-2H-furo[3,2-c]pyran-4-one
|
Molecular Formula | C27H36O7 | |
IUPAC Name* |
(2R)-6-[(1E,3E,5E)-6-[(2R,3R,3aR,4R,5R,6aR)-2-ethyl-3,4-dihydroxy-3,3a-dimethyl-2,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]hexa-1,3,5-trienyl]-2,3,3,7-tetramethyl-2H-furo[3,2-c]pyran-4-one
|
|
SMILES |
CC[C@@H]1[C@]([C@]2([C@H]([C@H](O[C@@H]2O1)/C=C/C=C/C=C/C3=C(C4=C(C(=O)O3)C([C@H](O4)C)(C)C)C)O)C)(C)O
|
|
InChI |
InChI=1S/C27H36O7/c1-8-19-27(7,30)26(6)22(28)18(33-24(26)34-19)14-12-10-9-11-13-17-15(2)21-20(23(29)32-17)25(4,5)16(3)31-21/h9-14,16,18-19,22,24,28,30H,8H2,1-7H3/b10-9+,13-11+,14-12+/t16-,18-,19-,22+,24-,26+,27+/m1/s1
|
|
InChIKey |
XEVKZSAFNVBSSK-JKWMLAQSSA-N
|
|
Synonyms |
Avertoxin D; J3.513.369K
|
|
CAS | NA | |
PubChem CID | 132605275 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.6 | ALogp: | 3.5 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 94.4 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.611 |
Caco-2 Permeability: | -4.895 | MDCK Permeability: | 0.00001100 |
Pgp-inhibitor: | 0.132 | Pgp-substrate: | 0.764 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.051 | Plasma Protein Binding (PPB): | 87.67% |
Volume Distribution (VD): | 1.347 | Fu: | 6.07% |
CYP1A2-inhibitor: | 0.242 | CYP1A2-substrate: | 0.69 |
CYP2C19-inhibitor: | 0.612 | CYP2C19-substrate: | 0.779 |
CYP2C9-inhibitor: | 0.872 | CYP2C9-substrate: | 0.958 |
CYP2D6-inhibitor: | 0.828 | CYP2D6-substrate: | 0.864 |
CYP3A4-inhibitor: | 0.784 | CYP3A4-substrate: | 0.868 |
Clearance (CL): | 1.538 | Half-life (T1/2): | 0.257 |
hERG Blockers: | 0.267 | Human Hepatotoxicity (H-HT): | 0.988 |
Drug-inuced Liver Injury (DILI): | 0.96 | AMES Toxicity: | 0.558 |
Rat Oral Acute Toxicity: | 0.808 | Maximum Recommended Daily Dose: | 0.951 |
Skin Sensitization: | 0.566 | Carcinogencity: | 0.017 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.017 |
Respiratory Toxicity: | 0.401 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001850 | 0.657 | D04JMQ | 0.214 | ||||
ENC005399 | 0.609 | D02YIZ | 0.210 | ||||
ENC005400 | 0.569 | D0Z1ZM | 0.206 | ||||
ENC005994 | 0.395 | D03HJK | 0.200 | ||||
ENC003144 | 0.373 | D0W2EK | 0.200 | ||||
ENC005401 | 0.371 | D0E9KA | 0.200 | ||||
ENC005765 | 0.359 | D0TG7I | 0.197 | ||||
ENC005764 | 0.359 | D0FG6M | 0.188 | ||||
ENC003250 | 0.247 | D06ZUP | 0.188 | ||||
ENC004533 | 0.241 | D0H2MO | 0.184 |